Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Capital Leases (2024 - 2025)

Historic Capital Leases for Denali Therapeutics (DNLI) over the last 2 years, with Q3 2025 value amounting to $5.6 million.

  • Denali Therapeutics' Capital Leases fell 136.74% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 million, marking a year-over-year decrease of 136.74%. This contributed to the annual value of $5.6 million for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Denali Therapeutics' Capital Leases is $5.6 million, which was down 136.74% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Denali Therapeutics' Capital Leases ranged from a high of $5.6 million in Q3 2024 and a low of $5.6 million during Q3 2025